1,349 Shares in Phreesia, Inc. (NYSE:PHR) Bought by BankPlus Trust Department

BankPlus Trust Department acquired a new stake in Phreesia, Inc. (NYSE:PHR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,349 shares of the company’s stock, valued at approximately $34,000.

A number of other large investors have also modified their holdings of PHR. Handelsbanken Fonder AB increased its stake in shares of Phreesia by 23.5% in the 4th quarter. Handelsbanken Fonder AB now owns 12,600 shares of the company’s stock valued at $317,000 after purchasing an additional 2,400 shares in the last quarter. Peregrine Capital Management LLC increased its position in shares of Phreesia by 0.8% in the fourth quarter. Peregrine Capital Management LLC now owns 319,327 shares of the company’s stock valued at $8,034,000 after buying an additional 2,531 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Phreesia in the fourth quarter valued at approximately $76,000. Rhumbline Advisers raised its stake in shares of Phreesia by 7.4% during the 4th quarter. Rhumbline Advisers now owns 83,631 shares of the company’s stock worth $2,104,000 after buying an additional 5,756 shares during the period. Finally, R Squared Ltd purchased a new position in shares of Phreesia during the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Stock Down 2.2 %

Shares of NYSE:PHR opened at $26.53 on Wednesday. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $27.35 and a two-hundred day moving average of $23.92. The stock has a market cap of $1.54 billion, a P/E ratio of -18.05 and a beta of 0.96.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same period last year, the business earned ($0.58) earnings per share. Phreesia’s revenue was up 16.6% compared to the same quarter last year. On average, research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

PHR has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a report on Friday, January 10th. Piper Sandler reiterated an “overweight” rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Truist Financial boosted their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Finally, Robert W. Baird dropped their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $31.15.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 3,495 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total value of $86,955.60. Following the completion of the transaction, the general counsel now directly owns 116,296 shares in the company, valued at approximately $2,893,444.48. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Weintraub sold 15,152 shares of Phreesia stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $21.01, for a total value of $318,343.52. Following the completion of the sale, the director now owns 242,827 shares in the company, valued at $5,101,795.27. This represents a 5.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 236,339 shares of company stock worth $6,292,359 in the last 90 days. Insiders own 5.80% of the company’s stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.